Write in a clean editor, then format for Journal of Experimental & Clinical Cancer Research in one click — DocuGuru applies the official BMC (BioMed Central) template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Journal of Experimental & Clinical Cancer Research is a peer-reviewed journal published by BMC (BioMed Central), covering Cancer-related molecular mechanisms research, MicroRNA in disease regulation, Cancer Cells and Metastasis. Over its lifetime it has published 4,624 papers, which have received 243,707 citations.
| Publisher | BMC (BioMed Central) |
|---|---|
| Reference style | Numbered (Vancouver) Numbered — [1], [2] in the text 1. Smith A, Jones B, Lee C. A representative article title. Journal of Experimental & Clinical Cancer Research. 2023;12(3):45–58.
Formats any DOI in Journal of Experimental & Clinical Cancer Research style. No sign-up. |
| Publishes research in | Cancer-related molecular mechanisms research MicroRNA in disease regulation Cancer Cells and Metastasis Cancer, Hypoxia, and Metabolism Circular RNAs in diseases |
| ISSN | 1756-9966 |
| Citation impact (2-yr) | 11.61 |
| h-index | 185 |
| i10-index | 3,596 |
| Article processing charge | $2,919 |
| Open access | Yes — indexed in DOAJ |
| Top institutions publishing here | Sun Yat-sen University |
| Journal website | link.springer.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions. It is also one of the most studied topics among cell biologists. An understanding of the underlying mechanism of apoptosis is important as it plays a pivotal role in the pathogenesis of many diseases. In some, the problem is due…
Targeting checkpoints of immune cell activation has been demonstrated to be the most effective approach for activation of anti-tumor immune responses. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), both inhibitory checkpoints commonly seen on activated T-cells have been found to be the most reliable targets for the treatment of cancer.…
Most chemotherapeutics elevate intracellular levels of reactive oxygen species (ROS), and many can alter redox-homeostasis of cancer cells. It is widely accepted that the anticancer effect of these chemotherapeutics is due to the induction of oxidative stress and ROS-mediated cell injury in cancer. However, various new therapeutic approaches targeting intracellular ROS levels have yielded mixed…
BACKGROUND: Quality of life in patients with breast cancer is an important outcome. This paper presents an extensive overview on the topic ranging from descriptive findings to clinical trials. METHODS: This was a bibliographic review of the literature covering all full publications that appeared in English language biomedical journals between 1974 and 2007. The search…
Tumor angiogenesis is necessary for the continued survival and development of tumor cells, and plays an important role in their growth, invasion, and metastasis. The tumor microenvironment-composed of tumor cells, surrounding cells, and secreted cytokines-provides a conducive environment for the growth and survival of tumors. Different components of the tumor microenvironment can regulate tumor development.…
